Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 502

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 2
Chunk 502
---
, and investor and public relations costs.

Amortization of intangible asset

Amortization of intangible asset relates to the technology acquired in the BioArkive acquisition. 

Other Income (Expense)

Interest income

Interest income consists of interest earned on our cash and cash equivalents balances and our marketable securities. The primary objective of our investment policy is capital preservation.

Other income (expense)

Other income (expense) consists of the amortization of premiums or accretion of discounts related to our marketable securities.

26

Results of Operations

Comparison of the Three Months Ended March 31, 2025 and 2024

The following table summarizes our results of operations for the periods indicated:

Three Months Ended March 31,Change20252024$% (in thousands, except percentages)Operating expensesResearch and development$11,472 $11,202 $270 2.4 %General and administrative4,006 4,116 (110)(2.7)%  Amortization of intangible asset7 7 — — %Total operating expenses15,485 15,325 160 1.0 %Loss from operations(15,485)(15,325)(160)1.0 %Other income (expense)Interest income439 805 (366)(45.5)%Other income, net— 213 (213)(100.0)%Net loss$(15,046)$(14,307)$(739)5.2 %

Research and Development

The following table summarizes the components of our research and development expenses for the periods indicated:

Three Months Ended March 31,Change20252024$%(in thousands, except percentages)Direct research and development expenses by program:IMM-1-104$4,258 $3,646 $612 16.8 %IMM-6-4151,624 1,028 596 58.0 %Other programs1,242 2,051 (809)(39.4)%Indirect research and development expenses:Employee-related costs3,223 3,540 (317)(9.0)%Stock-based compensation expense733 567 166 29.3 %Facilities and other expenses331 309 22 7.1 %Depreciation/amortization61 61 — — %Total research and development$11,472 $11,202 $270 2.4